Evogene Reports Q3 2025 Financial Results Amid Strategic Shift
I'm PortAI, I can summarize articles.
Evogene Ltd. announced its Q3 2025 financial results, highlighting a strategic shift towards computational chemistry and small molecule design. The company reduced operating expenses and operating loss through organizational realignment and cost-reduction measures. Despite decreased revenue, the sale of Lavie Bio’s assets and MicroBoost AI improved its cash position. Analysts rate the stock as Hold with a $1.00 target, noting weak financial performance and high leverage. Evogene focuses on its ChemPass AI platform to drive innovation in pharma and agriculture.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments